

Ailsa L Hart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5813505/publications.pdf>

Version: 2024-02-01

136
papers

13,537
citations

53660

45
h-index

24179

110
g-index

140
all docs

140
docs citations

140
times ranked

19711
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool. <i>Gut</i> , 2022, 71, 705-715.	6.1	12
2	Perception of Cancer Risk and Management Practice for Colitis-associated Dysplasia Is Influenced by Colonoscopy Experience and Workplace Affiliation: Results of an International Clinician Survey. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 39-48.	0.6	3
3	A Multidisciplinary Approach to Rectal Cancer Treatment in Ulcerative Colitis Results in High Rate of Restorative Minimally Invasive Surgery. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 244-250.	0.6	1
4	Systematic review: the association between the gut microbiota and medical therapies in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 26-48.	1.9	23
5	Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 922-930.	0.6	8
6	Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 464-478.	1.9	73
7	The Essential Role of a Multidisciplinary Approach in Inflammatory Bowel Diseases: Combined Medical-Surgical Treatment in Complex Perianal Fistulas in CD. <i>Clinics in Colon and Rectal Surgery</i> , 2022, 35, 021-031.	0.5	1
8	How Should Pain, Fatigue, and Emotional Wellness Be Incorporated Into Treatment Goals for Optimal Management of Inflammatory Bowel Disease?. <i>Gastroenterology</i> , 2022, 162, 1439-1451.	0.6	25
9	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 254-261.	3.7	18
10	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	3.7	100
11	IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2619-2627.e1.	2.4	9
12	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	5.8	48
13	Systematic Review: The Impact and Importance of Body Composition in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1475-1492.	0.6	20
14	Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 576-584.	3.7	17
15	Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn's disease who became pregnant: A post hoc analysis. <i>United European Gastroenterology Journal</i> , 2022, 10, 485-495.	1.6	3
16	Randomized Trial of Ciprofloxacin Doxycycline and Hydroxychloroquine Versus Budesonide in Active Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2700-2711.	1.1	10
17	Ulcerative Colitis Narrative Global Survey Findings: Communication Gaps and Agreements Between Patients and Physicians. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1096-1106.	0.9	15
18	Current review of the management of fistulising perianal Crohn's disease. <i>Frontline Gastroenterology</i> , 2021, 12, 515-523.	0.9	9

#	ARTICLE	IF	CITATIONS
19	Are we addressing the top 10 research priorities in IBD?. <i>Frontline Gastroenterology</i> , 2021, 12, 564-569.	0.9	6
20	Clinician Administered and Self-Report Survey Both Effective for Identifying Fecal Incontinence in Patients with Inflammatory Bowel Disease. <i>Digestive Diseases and Sciences</i> , 2021, 66, 2024-2031.	1.1	9
21	The Incidence and Prevalence of Human Papilloma Virus-associated Cancers in IBD. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 34-39.	0.9	19
22	Management of inflammatory bowel disease associated colonic dysplasia: factors predictive of patient choice and satisfaction. <i>Colorectal Disease</i> , 2021, 23, 882-893.	0.7	3
23	What is the patient's and multidisciplinary team's perspective on telephone clinics?. <i>British Journal of Health Care Management</i> , 2021, 27, 26-31.	0.1	5
24	The pouch behaving badly: management of morbidity after ileal pouch-anal anastomosis. <i>Colorectal Disease</i> , 2021, 23, 1193-1204.	0.7	5
25	Ulcerative colitis: an update. <i>Clinical Medicine</i> , 2021, 21, 135-139.	0.8	87
26	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	6.1	153
27	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 218-224.	3.7	111
28	Chronic pain in patients with inflammatory bowel disease. <i>Pain</i> , 2021, 162, 2466-2471.	2.0	14
29	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	3.7	23
30	The Microbiome as a Therapy in Pouchitis and Ulcerative Colitis. <i>Nutrients</i> , 2021, 13, 1780.	1.7	21
31	Patient perceptions of joint medical-surgical assessment in a tertiary referral clinic for inflammatory bowel disease. <i>British Journal of Health Care Management</i> , 2021, 27, 146-151.	0.1	1
32	Predicting Colorectal Cancer Occurrence in IBD. <i>Cancers</i> , 2021, 13, 2908.	1.7	26
33	Prognostic factors associated with unhealed perineal wounds post-proctectomy for perianal Crohn's disease: a two-centre study. <i>Colorectal Disease</i> , 2021, 23, 2091-2099.	0.7	1
34	Prospective randomised controlled trial of adults with perianal fistulising Crohn's disease and optimised therapeutic infliximab levels: PROACTIVE trial study protocol. <i>BMJ Open</i> , 2021, 11, e043921.	0.8	4
35	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102849.	2.5	12
36	Supported online self-management versus care as usual for symptoms of fatigue, pain and urgency/incontinence in adults with inflammatory bowel disease (IBD-BOOST): study protocol for a randomised controlled trial. <i>Trials</i> , 2021, 22, 516.	0.7	11

#	ARTICLE	IF	CITATIONS
37	Enhanced neoplasia detection in chronic ulcerative colitis: the ENDCaP-C diagnostic accuracy study. Efficacy and Mechanism Evaluation, 2021, 8, 1-88.	0.9	0
38	International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPs Survey. Inflammatory Bowel Diseases, 2021, 27, 1942-1953.	0.9	30
39	Quantitative Magnetic Resonance Imaging in Perianal Crohn's Disease at 1.5 and 3.0 T: A Feasibility Study. Diagnostics, 2021, 11, 2135.	1.3	2
40	Strategies to Distinguish Perianal Fistulas Related to Crohn's Disease From Cryptoglandular Disease: Systematic Review With Meta-Analysis. Inflammatory Bowel Diseases, 2021, , .	0.9	4
41	Editorial: a pipe dream fulfilled? A therapeutic option for fatigue in IBD. Alimentary Pharmacology and Therapeutics, 2021, 53, 342-343.	1.9	1
42	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. Gastroenterology, 2020, 158, 189-199.	0.6	249
43	Commentary: safety of anti-TNF use in pregnancy. Alimentary Pharmacology and Therapeutics, 2020, 51, 205-206.	1.9	0
44	Multidisciplinary management of the nocebo effect in biosimilar-treated IBD patients: Results of a workshop from the NOCE-BIO consensus group. Digestive and Liver Disease, 2020, 52, 138-142.	0.4	21
45	Multiomic features associated with mucosal healing and inflammation in paediatric Crohn's disease. Alimentary Pharmacology and Therapeutics, 2020, 52, 1491-1502.	1.9	20
46	HPV-related Cancers in Inflammatory Bowel Disease: Association Not Yet Causation. Inflammatory Bowel Diseases, 2020, 26, e102-e102.	0.9	0
47	International Organization for the Study of Inflammatory Bowel Disease: Global Strategies for Telemedicine and Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2020, 14, S780-S784.	0.6	20
48	Systematic review with meta-analysis: IBD-associated colonic dysplasia prognosis in the videoendoscopic era (1990 to present). Alimentary Pharmacology and Therapeutics, 2020, 52, 5-19.	1.9	22
49	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. Gut, 2020, 69, gutjnl-2020-321927.	6.1	28
50	Bacteroides thetaiotaomicron-derived outer membrane vesicles promote regulatory dendritic cell responses in health but not in inflammatory bowel disease. Microbiome, 2020, 8, 88.	4.9	76
51	Clinical Trials [and Tribulations]: The Immediate Effects of COVID-19 on IBD Clinical Research Activity in the UK. Journal of Crohn's and Colitis, 2020, 14, 1769-1776.	0.6	13
52	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. Journal of Crohn's and Colitis, 2020, 14, 1037-1048.	0.6	55
53	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. Gastroenterology, 2020, 159, 6-13.e6.	0.6	185
54	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 2020, 69, 984-990.	6.1	232

#	ARTICLE	IF	CITATIONS
55	A proposed tailored investigational algorithm for women treated for gynaecological cancer with long-term gastrointestinal consequences. <i>Supportive Care in Cancer</i> , 2020, 28, 4881-4889.	1.0	7
56	Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience. <i>Annals of Gastroenterology</i> , 2020, 33, 170-177.	0.4	13
57	The use of 5-aminosalicylates in Crohn's disease: a retrospective study using the UK Clinical Practice Research Datalink. <i>Annals of Gastroenterology</i> , 2020, 33, 500-507.	0.4	4
58	Evolutionary history of human colitis-associated colorectal cancer. <i>Gut</i> , 2019, 68, 985-995.	6.1	97
59	A multicentre prospective cohort study assessing the effectiveness of budesonide MMX [®] (Cortiment [®] MMX [®]) for active, mild-to-moderate ulcerative colitis. <i>United European Gastroenterology Journal</i> , 2019, 7, 1171-1182.	1.6	9
60	The application of omics techniques to understand the role of the gut microbiota in inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481882225.	1.4	49
61	A blood-based prognostic biomarker in IBD. <i>Gut</i> , 2019, 68, 1386-1395.	6.1	132
62	Predictors of anti-TNF treatment failure in anti-TNF-naïve patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	3.7	431
63	Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1181-1187.	1.9	42
64	The gut virome: the "missing link" between gut bacteria and host immunity?. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481983662.	1.4	127
65	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 773.	3.8	129
66	Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn's disease: the LIRIC Trial. <i>Gut</i> , 2019, 68, 1774-1780.	6.1	56
67	Unmet Medical Needs in Ulcerative Colitis: An Expert Group Consensus. <i>Digestive Diseases</i> , 2019, 37, 266-283.	0.8	63
68	Gaps in knowledge and future directions for the use of faecal microbiota transplant in the treatment of inflammatory bowel disease. <i>Therapeutic Advances in Gastroenterology</i> , 2019, 12, 175628481989103.	1.4	15
69	Editorial: how safe is it to administer the BCG vaccination to babies exposed to anti-TNF \pm medications antenatally?. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1239-1239.	1.9	1
70	International consensus conference on stool banking for faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2019, 68, 2111-2121.	6.1	290
71	Current Practices in Ileal Pouch Surveillance for Patients With Ulcerative Colitis: A Multinational, Retrospective Cohort Study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 735-743.	0.6	24
72	How Quickly Do Inflammatory Bowel Disease Medications Really Work?. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 34-35.	2.4	4

#	ARTICLE	IF	CITATIONS
73	Cumulative burden of inflammation predicts colorectal neoplasia risk in ulcerative colitis: a large single-centre study. <i>Gut</i> , 2019, 68, 414-422.	6.1	117
74	Developing a core outcome set for fistulising perianal Crohn's disease. <i>Gut</i> , 2019, 68, 226-238.	6.1	64
75	Medical-surgical Combined Approach in Perianal Fistulizing Crohn's Disease (CD): Doing it Together. <i>Current Drug Targets</i> , 2019, 20, 1373-1383.	1.0	3
76	Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn's disease patients: the METRIC diagnostic accuracy study. <i>Health Technology Assessment</i> , 2019, 23, 1-162.	1.3	10
77	Challenges in screening for latent tuberculosis in inflammatory bowel disease prior to biologic treatment: a UK cohort study. <i>Frontline Gastroenterology</i> , 2018, 9, 234-240.	0.9	11
78	Standardising assessment and documentation of pouchoscopy. <i>Frontline Gastroenterology</i> , 2018, 9, 309-314.	0.9	35
79	Long-term follow-up of the use of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis. <i>Frontline Gastroenterology</i> , 2018, 9, 154-158.	0.9	23
80	Incidence and Long-term Implications of Prepouch Ileitis: An Observational Study. <i>Diseases of the Colon and Rectum</i> , 2018, 61, 472-475.	0.7	14
81	A Systematic Review: The Management and Outcomes of Ileal Pouch Strictures. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 369-375.	0.6	20
82	The Effect of Vitamin D on Intestinal Inflammation and Faecal Microbiota in Patients with Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 963-972.	0.6	78
83	Faecal microbiota transplantation as a treatment for inflammatory bowel disease: a national survey of adult and paediatric gastroenterologists in the UK. <i>Frontline Gastroenterology</i> , 2018, 9, 250-255.	0.9	7
84	Meeting update: faecal microbiota transplantation – “bench, bedside, courtroom?”. <i>Frontline Gastroenterology</i> , 2018, 9, 45-48.	0.9	4
85	Evaluation of an inflammatory bowel disease service to drive sustainable improvement. <i>British Journal of Health Care Management</i> , 2018, 24, 476-478.	0.1	0
86	Biological therapy for the treatment of prepouch ileitis: a retrospective observational study from three centers. <i>Clinical and Experimental Gastroenterology</i> , 2018, Volume 11, 461-465.	1.0	7
87	Volume assessment magnetic resonance imaging technique for monitoring perianal Crohn's fistulas. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481879360.	1.4	3
88	PTU-099...Evaluation to support service improvement for patients with inflammatory bowel disease at ST Mark's hospital. , 2018, , .		0
89	Twenty years of biological therapy in an patient with IBD. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-221994.	0.2	0
90	Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 1051-1058.	0.6	12

#	ARTICLE	IF	CITATIONS
91	A New Look at Familial Risk of Inflammatory Bowel Disease in the Ashkenazi Jewish Population. <i>Digestive Diseases and Sciences</i> , 2018, 63, 3049-3057.	1.1	13
92	The role of multimodal treatment in Crohn's disease patients with perianal fistula: a multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 941-950.	1.9	24
93	The use of faecal microbiota transplant as treatment for recurrent or refractory <i>Clostridium difficile</i> infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. <i>Journal of Hospital Infection</i> , 2018, 100, S1-S31.	1.4	38
94	Reliability among central readers in the evaluation of endoscopic disease activity in pouchitis. <i>Gastrointestinal Endoscopy</i> , 2018, 88, 360-369.e2.	0.5	29
95	Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 548-558.	3.7	143
96	Anti-TNF Therapy in Crohn's Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2244.	1.8	177
97	Biofeedback in patients with ileoanal pouch dysfunction: a specialist centre experience. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 665-669.	0.6	10
98	Does the Internet promote the unregulated use of fecal microbiota transplantation: a potential public health issue?. <i>Clinical and Experimental Gastroenterology</i> , 2018, Volume 11, 179-183.	1.0	6
99	The use of faecal microbiota transplant as treatment for recurrent or refractory <i>Clostridium difficile</i> infection and other potential indications: joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. <i>Gut</i> , 2018, 67, 1920-1941.	6.1	248
100	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 256-261.	9.4	943
101	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. <i>Nature Genetics</i> , 2017, 49, 186-192.	9.4	153
102	European consensus conference on faecal microbiota transplantation in clinical practice. <i>Gut</i> , 2017, 66, 569-580.	6.1	793
103	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 649-670.	0.6	1,324
104	Pilot study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas. <i>International Journal of Surgery</i> , 2017, 41, 127-133.	1.1	3
105	Review of local injection of anti-TNF for perianal fistulising Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2017, 32, 1539-1544.	1.0	28
106	Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: a randomised controlled, open-label, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 785-792.	3.7	196
107	In Patients With Perianal Crohn's Fistulas, What Are the Outcomes When "Radiological Healing" Is Achieved? Does Radiological Healing of Perianal Crohn's Fistulas Herald the Time Point for Stopping a Biologic?. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1506-1506.	0.6	6
108	What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 204-211.	0.6	83

#	ARTICLE	IF	CITATIONS
109	Assessing online information sources on ileal pouch-anal anastomosis. <i>Gastrointestinal Nursing</i> , 2017, 15, 20-22.	0.0	1
110	Management of Perianal Crohn's Disease in the Biologic Era. , 2017, , 1-27.		1
111	Tight junctions in inflammatory bowel diseases and inflammatory bowel disease associated colorectal cancer. <i>World Journal of Gastroenterology</i> , 2016, 22, 3117.	1.4	351
112	A review of endoscopic balloon dilatation techniques for treating Crohn's strictures: time to standardise therapy. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 1101-1107.	1.4	2
113	Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000092.	1.1	7
114	Endoscopic Dilatation of Crohn's Anastomotic Strictures is Effective in the Long Term, and Escalation of Medical Therapy Improves Outcomes in the Biologic Era. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 1172-1178.	0.6	51
115	Chemokine (C-C Motif) Receptor 2 Mediates Dendritic Cell Recruitment to the Human Colon but Is Not Responsible for Differences Observed in Dendritic Cell Subsets, Phenotype, and Function Between the Proximal and Distal Colon. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2016, 2, 22-39.e5.	2.3	27
116	Anti-TNF drug and antidrug antibody level monitoring in IBD: a practical guide. <i>Frontline Gastroenterology</i> , 2016, 7, 122-128.	0.9	36
117	Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease – the Unmet Needs. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 758-765.	0.6	49
118	The gut microbiota and host health: a new clinical frontier. <i>Gut</i> , 2016, 65, 330-339.	6.1	1,719
119	Compartment-specific immunity in the human gut: properties and functions of dendritic cells in the colon versus the ileum. <i>Gut</i> , 2016, 65, 256-270.	6.1	72
120	Multimodal treatment of perianal fistulas in Crohn's disease: seton versus anti-TNF versus advancement plasty (PISA): study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 366.	0.7	40
121	Faecal incontinence intervention study (FINS): self-management booklet information with or without nurse support to improve continence in people with inflammatory bowel disease: study protocol for a randomized controlled trial. <i>Trials</i> , 2015, 16, 444.	0.7	8
122	Determining Predictors for Intra-abdominal Septic Complications Following Ileocolonic Resection for Crohn's Disease – Considerations in Pre-operative and Peri-operative Optimisation Techniques to Improve Outcome. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 483-491.	0.6	92
123	Forty-Year Analysis of Colonoscopic Surveillance Program for Neoplasia in Ulcerative Colitis: An Updated Overview. <i>American Journal of Gastroenterology</i> , 2015, 110, 1022-1034.	0.2	227
124	IBD: reproductive health, pregnancy and lactation. <i>Frontline Gastroenterology</i> , 2015, 6, 38-43.	0.9	6
125	Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. <i>Nature Genetics</i> , 2015, 47, 979-986.	9.4	1,965
126	Republished curriculum based clinical review: IBD: reproductive health, pregnancy and lactation. <i>Postgraduate Medical Journal</i> , 2015, 91, 230-235.	0.9	2

#	ARTICLE	IF	CITATIONS
127	Clinical Trials in Ulcerative Colitis: A Historical Perspective. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 580-588.	0.6	48
128	Defining the optimal design of the inflammatory bowel disease multidisciplinary team: results from a multicentre qualitative expert-based study. <i>Frontline Gastroenterology</i> , 2015, 6, 290-297.	0.9	23
129	Low-Grade Dysplasia in Ulcerative Colitis: Risk Factors for Developing High-Grade Dysplasia or Colorectal Cancer. <i>American Journal of Gastroenterology</i> , 2015, 110, 1461-1471.	0.2	118
130	A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. <i>Gut</i> , 2014, 63, 1381-1392.	6.1	317
131	METRIC (MREnterography or uTRasound in Crohn's disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over. <i>BMC Gastroenterology</i> , 2014, 14, 142.	0.8	36
132	Clinical trials in luminal Crohn's disease: A historical perspective. <i>Journal of Crohn's and Colitis</i> , 2014, 8, 1339-1350.	0.6	23
133	Vitamin D and Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 459-460.	0.9	5
134	Long-term MRI-guided combined anti-TNF- α and thiopurine therapy for Crohn's perianal fistulas. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1825-1834.	0.9	114
135	Topical tacrolimus in the treatment of perianal Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2007, 13, 245-253.	0.9	98
136	Use of Probiotics in the Treatment of Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 111-119.	1.1	94